Open AccessAbaloparatide followed by alendronate in women ≥80 years with osteoporosis: post hoc analysis of ACTIVExtend
Author(s) -
Susan L. Greenspan,
Lorraine A. Fitzpatrick,
Bruce Mitlak,
Yamei Wang,
Nicholas C. Harvey,
Chad Deal,
Felicia Cosman,
Michael R. McClung
Publication year - 2020
Publication title -
menopause
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.086
H-Index - 103
eISSN - 1530-0374
pISSN - 1072-3714
DOI - 10.1097/gme.0000000000001593
Subject(s) - medicine , bone mineral , osteoporosis , placebo , femoral neck , incidence (geometry) , post hoc analysis , adverse effect , bone density , alendronic acid , bone remodeling , surgery , physics , alternative medicine , pathology , optics
Fracture risk increases with age, but few studies focus on persons ≥80 years. In the ACTIVE trial, treatment with abaloparatide for 18 months reduced osteoporotic fracture risk and increased bone mineral density. These effects were maintained with 24 months alendronate treatment in ACTIVExtend. We postulated that similar improvements in bone mineral density and safety would be demonstrated in women ≥80 years.